Surgery avoidable with immunotherapy in mismatch repair-deficient tumors

Nature Medicine, Published online: 22 May 2025; doi:10.1038/d41591-025-00033-9

In a phase 2 trial, complete responses to neoadjuvant dostarlimab allowed most patients with early-stage solid tumors to avoid surgery, which allowed preservation of affected organs.